Should women with HIV, or at high risk of contracting HIV, use progestogen-containing contraception?

BMJ (Online)

Volumn 347, Issue , 2013, Pages

  Giles, Sarah Louise ^a,b   Lester, Felicia ^c  

^a Kitovu Hospital   (Uganda)

^b c/o Uganda River of Life Ministries ^*  (Uganda)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; INJECTABLE CONTRACEPTIVE AGENT; ORAL CONTRACEPTIVE AGENT;

CONDOM; DISEASE ASSOCIATION; DISEASE COURSE; HEALTH CARE ACCESS; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; MEDICAL RESEARCH; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SEXUAL COUNSELING; VIRUS INFECTIVITY; VIRUS SHEDDING; VIRUS TRANSMISSION;

CONTRACEPTION; CONTRACEPTIVE AGENTS; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; PROGESTINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVIEW LITERATURE AS TOPIC;

EID: 84888273311     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f6695     Document Type: Review

References (25)

1. United Nations Department of Economic and Social Affairs, Population Division. World contraceptive use 2011. www.un.org/esa/population/publications/ contraceptive2011/wallchart-front.pdf.
2. Watts DH, Park JG, Cohn SE, Yu S, Hitti J, Stek A, et al. Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Contraception 2008;77:84-90.
3. World Health Organization, Department of Reproductive Health. Medical eligibility criteria for contraceptive use . 4th ed. WHO, 2009.
4. Blish CA, Baeten JM. Hormonal contraception and HIV-1 transmission. Am J Reprod Immunol 2011;65:302-7.
5. World Health Organization, Department of Reproductive Health. WHO Technical statement: Hormonal contraception and HIV . WHO, 2012.
6. Centers for Disease Control and Prevention (CDC). Update to CDC's US Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV. MMWR Morb Mortal Wkly Rep 2012;61:449-52.
7. Polis C, Curtis K. Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. Lancet Infect Dis 2013;13:797-808.
8. Baeten JM, Benki S, Chohan V, Lavreys L, McClelland RS, Mandaliya K, et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS 2007;21:1771-7.
9. McCoy SI, Zheng W, Montgomery ET, Blanchard K, van der Straten A, de Bruyn G, et al. Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. AIDS 2013;27:1001-9.
10. Morrison CS, Chen PL, Kwok C, Richardson BA, Chipato T, Mugerwa R, et al. Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS 2010;24:1778-81.
11. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Hormonal contraceptive use and risk of HIV-1 transmission: a prospective cohort analysis. Lancet Infect Dis 2012;12:19-26.
12. Crook A, Rees H, Ramjee G, et al. Hormonal contraception and risk of HIV: an analysis of data from the Microbicides Development Programme Trial. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta . Abstract 28, 2013.
13. Draper BH, Morroni C, Hoffman M, Smit J, Beksinska M, Hapgood J, et al. Depot medroxyprogesterone versus norethisterone oenanthate for long-acting progestogenic contraception. Cochrane Database Syst Rev 2006;(3):CD005214. doi:10.1002/14651858.CD005214.pub2.
14. Hapgood JP, Koubovec D, Louw A, Africander D. Not all progestins are the same: implications for usage. Trends Pharmacol Sci 2004;25:554-7.
15. Curtis KM, Nanda K, Kapp N. Safety of hormonal and intrauterine methods of contraception for women with HIV/AIDS: a systematic review. AIDS 2009;23(suppl 1):S55-67.
16. Polis CB, Phillips SJ, Curtis KM. Hormonal contraceptive use and female-to-male HIV transmission: a systematic review of the epidemiologic evidence. AIDS 2013;27:493-505.
17. Phillips SJ, Curtis KM, Polis CB. Effect of hormonal contraceptive methods on HIV disease progression: a systematic review. AIDS 2013;27:787-94.
18. Stringer EM, Kaseba C, Levy J, Sinkala M, Goldenberg RL, Chi BH, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol 2007;197:144.e1-8.
19. Stringer EM, Levy J, Sinkala M, Chi BH, Matongo I, Chintu N, et al. HIV disease progression by hormonal contraceptive method: secondary analysis of a randomized trial. AIDS 2009;23:1377-82.
20. Morrison CS, Chen PL, Nankya I, Rinaldi A, Van Der Pol B, Ma YR, et al. Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe. J Acquir Immune Defic Syndr 2011;57:157-64.
21. Polis CB, Wawer MJ, Kiwanuka N, Laeyendecker O, Kagaayi J, Lutalo T, et al. Effect of hormonal contraceptive use on HIV progression in female HIV seroconverters in Rakai, Uganda. AIDS 2010;24:1937-44.
22. Stringer EM, Giganti M, Carter RJ, El-Sadr W, Abrams EJ, Stringer JS for the MTCT-Plus Initiative. Hormonal contraception and HIV disease progression: a multicountry cohort analysis of the MTCT Plus Initiative. AIDS 2009;23(suppl 1):S69-77.
23. Day S, et al. Is depot medroxyprogesterone acetate likely to increase infectivity in HIV-1+ women receiving ART? 20th Conference on Retroviruses and Opportunistic Infections, Atlanta. Abstract 29, 2013.
24. Polis C, Heffron R. What have the epidemiological studies taught us about hormonal contraceptives and HIV-related risks? 20th Conference on Retroviruses and Opportunistic Infections, Atlanta . Presentation 113, 2013.
25. Butler AR, Smith JA, Polis CB, Gregson S, Stanton D, Hallett TB. Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk. AIDS 2013;27:105-13.